These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 31466300)
1. BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors. Schreck KC; Grossman SA; Pratilas CA Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31466300 [TBL] [Abstract][Full Text] [Related]
2. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Roskoski R Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796 [TBL] [Abstract][Full Text] [Related]
3. Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With Fusco MJ; Piña Y; Macaulay RJ; Sahebjam S; Forsyth PA; Peguero E; Walko CM Cancer Control; 2021; 28():10732748211040013. PubMed ID: 34620004 [TBL] [Abstract][Full Text] [Related]
4. Sustained Tumor Control With MAPK Inhibition in Berzero G; Bellu L; Baldini C; Ducray F; Guyon D; Eoli M; Silvani A; Dehais C; Idbaih A; Younan N; Nguyen-Them L; Gaillard S; Pasqualetti F; Lepage-Seydoux C; Sekkate S; Tresca P; Kas A; Gratieux J; Ammari S; Saragoussi E; Savatovsky J; Delattre JY; Hoang-Xuan K; Meyronet D; Villa C; Bielle F; Sanson M; Touat M; Di Stefano AL Neurology; 2021 Aug; 97(7):e673-e683. PubMed ID: 34088874 [TBL] [Abstract][Full Text] [Related]
5. RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events. Schreck KC; Patel MP; Wemmer J; Grossman SA; Peters KB Neurooncol Pract; 2020 Jul; 7(4):369-375. PubMed ID: 32765888 [TBL] [Abstract][Full Text] [Related]
9. Dabrafenib plus Trametinib in Pediatric Glioma with Bouffet E; Hansford JR; Garrè ML; Hara J; Plant-Fox A; Aerts I; Locatelli F; van der Lugt J; Papusha L; Sahm F; Tabori U; Cohen KJ; Packer RJ; Witt O; Sandalic L; Bento Pereira da Silva A; Russo M; Hargrave DR N Engl J Med; 2023 Sep; 389(12):1108-1120. PubMed ID: 37733309 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722 [TBL] [Abstract][Full Text] [Related]
11. Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib. Noeparast A; Teugels E; Giron P; Verschelden G; De Brakeleer S; Decoster L; De Grève J Oncotarget; 2017 Sep; 8(36):60094-60108. PubMed ID: 28947956 [TBL] [Abstract][Full Text] [Related]
12. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064 [TBL] [Abstract][Full Text] [Related]
13. Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. Negrao MV; Raymond VM; Lanman RB; Robichaux JP; He J; Nilsson MB; Ng PKS; Amador BE; Roarty EB; Nagy RJ; Banks KC; Zhu VW; Ng C; Chae YK; Clarke JM; Crawford JA; Meric-Bernstam F; Ignatius Ou SH; Gandara DR; Heymach JV; Bivona TG; McCoach CE J Thorac Oncol; 2020 Oct; 15(10):1611-1623. PubMed ID: 32540409 [TBL] [Abstract][Full Text] [Related]
14. Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition. Allen A; Qin ACR; Raj N; Wang J; Uddin S; Yao Z; Tang L; Meyers PA; Taylor BS; Berger MF; Yaeger R; Reidy-Lagunes D; Pratilas CA PLoS One; 2019; 14(6):e0217399. PubMed ID: 31158244 [TBL] [Abstract][Full Text] [Related]
16. Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation. Rutkowski P; Blank C Expert Opin Drug Saf; 2014 Sep; 13(9):1249-58. PubMed ID: 25014231 [TBL] [Abstract][Full Text] [Related]
17. Encorafenib plus binimetinib in patients with Riely GJ; Ahn MJ; Felip E; Ramalingam SS; Smit EF; Tsao AS; Alcasid A; Usari T; Wissel PS; Wilner KD; Johnson BE Future Oncol; 2022 Mar; 18(7):781-791. PubMed ID: 34918546 [TBL] [Abstract][Full Text] [Related]
18. Dabrafenib plus trametinib in patients with BRAF Wen PY; Stein A; van den Bent M; De Greve J; Wick A; de Vos FYFL; von Bubnoff N; van Linde ME; Lai A; Prager GW; Campone M; Fasolo A; Lopez-Martin JA; Kim TM; Mason WP; Hofheinz RD; Blay JY; Cho DC; Gazzah A; Pouessel D; Yachnin J; Boran A; Burgess P; Ilankumaran P; Gasal E; Subbiah V Lancet Oncol; 2022 Jan; 23(1):53-64. PubMed ID: 34838156 [TBL] [Abstract][Full Text] [Related]
20. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma. Rose AAN Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]